Progestins and breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 65, Issue 1-6, 1998, Pages 225-235

  Pasqualini, J R ^a   Paris, J ^b   Sitruk Ware, R ^c   Chetrite, G ^a   Botella, J ^b  

^a Institut de Puericulture   (France)

^b Les Industries   (France)

^c Exelgyn SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALGESTONE; ANDROCAR; ANDROSTANE DERIVATIVE; CHLORMADINONE; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DEMEGESTONE; DUPHASTON 10; ESTRADIOL; ESTRONE; ETYNODIOL DIACETATE; GESTAGEN; GESTONORONE CAPROATE; GESTRINONE; HYDROXYPROGESTERONE; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE CAPROATE; MEGESTROL ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETHISTERONE ENANTATE; PHERLON; PROGESTERONE; PROMEGESTONE; RETROPROGESTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TIBOLONE; TRIMEGESTONE; UNCLASSIFIED DRUG;

BREAST CANCER; CONFERENCE PAPER; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOPHYSIOLOGY; RECEPTOR AFFINITY;

EID: 0032052786     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00028-4     Document Type: Conference Paper

References (131)

1. Segaloff, A., Hormones and mammary carcinogenesis. In Breast Cancer 2: Advances in Research and Treatment, ed. W. L. McGuire. Plenum Press, New York, 1978, pp. 1-22.
2. Kirschner, M. A., The role of hormones in the development of human breast cancer. In Breast Cancer 3: Advances in Research and Treatment, Current Topics, ed. W. L. McGuire. Plenum Press, New York, 1979, pp. 199-226.
3. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Research. 48:1988;246-253.
4. Raam S., Robert N., Pappas C. A., Tamura H. Defective estrogen receptors in human mammary cancers: their significance in defining hormone dependence. Journal of the National Cancer Institute. 80:1988;756-761.
5. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W., McGuire W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Research. 51:1991;105-109.
6. McGuire W. L., Chamness G. C., Fuqua S. A. W. Abnormal estrogen receptor in clinical breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 43:1992;243-247.
7. Castles C. G., Fuqua S. A. W., Klotz D. M., Hill S. M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Research. 53:1993;5934-5939.
8. Murphy L. C., Dotzlaw H., Leygue E., Douglas D., Coutts A., Watson P. H. Minireview: Estrogen receptor variants and mutations. Journal of Steroid Biochemistry and Molecular Biology. 62:1997;363-372.
9. Edwards D. P., Chamness G. C., McGuire W. L. Estrogen and progesterone receptors in breast cancer. Biochimica Biophysica Acta. 560:1979;457-486.
10. Litherland S., Jackson I. M. Antiestrogens in the management of hormone-dependent cancer. Cancer Treatment Reviews. 15:1988;183-194.
11. Hall J. M., Lee M. K., Newman B., Horrow J. E., Anderson L. A., Huey B., King M. C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250:1990;1684-1689.
12. Cropp C. S., Nevanlinna H. A., Pyrhönen S., Stenman U.-H., Salmikangas P., Albertsen H., White R., Callahan R. Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Research. 54:1994;2548-2551.
13. Wooster R., Neuhauson S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D., Fields P., Marshall G., Narod S., Lenoir G. M., Lynch H., Feunteun J., Devilee P., Cornelisse C. J., Menko F. H., Daly P. A., Ormiston W., McManus R., Pye C., Lewis C. M., Cannon-Albright L. A., Peto J., Ponder B. A. J., Skolnick M. H., Easton D. F., Goldgar D. E., Stratton M. R. Localization of a breast cancer susceptibility gene, BRCA2 to chromosome 13q12-13. Science. 265:1994;2088-2090.
14. Beatson G. T. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. The Lancet. 2:1896;104-107.
15. Huggins C., Dao T. Adrenalectomy and oophorectomy in the treatment of advanced carcinoma of the breast. Journal of the American Medical Association. 151:1953;1388-1394.
16. Longacre T. A., Bartow S. A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. American Journal of Surgical Patholology. 10:1986;382-393.
17. Topper Y. J., Freeman C. S. Multiple hormone interactions in the developmental biology of the mammary gland. Physiological Reviews. 60:1980;1049-1106.
18. van Bogaert L. J. Effect of hormone on human mammary duct in vivo. Hormone and Metabolic Research. 10:1978;337-340.
19. McManus M. J., Welsch C. W. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer. 54:1984;1920-1927.
20. Laidlaw I. J., Clarke R. B., Howell A., Owen A. W. M. C., Potten C. S., Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology. 136:1995;164-171.
21. Gompel A., Malet C., Spritzer P., Lalardrie J.-P., Kuttenn F., Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. Journal of Clinical Endocrinology and Metabolism. 63:1986;1174-1180.
22. Longman S. M., Buehring G. C. Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth. Cancer. 59:1987;281-287.
23. Jones B., Russo J. Influence of steroid hormones on the growth fraction of human breast carcinomas. American Journal of Clinical Pathology. 88:1987;132-138.
24. Botella J., Duranti E., Duc I., Cognet A. M., Delansorne R., Paris J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T-47D human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 50:1994;41-47.
25. Vignon F., Bardon S., Chalbos D., Rochefort H. Antiestrogenic effect of R-5020, a synthetic progestin in human breast cancer cells in culture. Journal of Clinical Endocrinology and Metabolism. 56:1983;1124-1130.
26. Horwitz K. B., Freidenberg G. R. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T-47Dco human breast cancer cells by progestins: implication for endocrine therapies. Cancer Research. 45:1985;167-173.
27. Murphy L. C., Dotzlaw H., Alkhalaf M., Coutts A., Millar T., Wong M. S. J., Gong Y., Murphy L. J. Mechanisms of growth inhibition by antiestrogens and progestins in human breast and endometrial cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 43:1992;117-121.
28. Musgrove E. A., Lee C. S., Sutherland R. L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos and c-myc genes. Molecular and Cellular Biology. 11:1991;5032-5043.
29. Jeng M.-H., Parker C. J., Jordan V. C. Estrogenic potential of progestins in oral contracteptives to stimulate human breast cancer cell proliferation. Cancer Research. 52:1992;6539-6546.
30. Kalkhoven E., Kwakkenbos-Isbrücker L., de Laat S. W., van der Saag P. T., van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Molecular and Cellular Endocrinology. 102:1994;45-52.
31. Papa V., Reese C. C., Brunetti A., Vigneri R., Siiteri P. K., Goldfine I. D. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells. Cancer Research. 50:1990;7858-7862.
32. Hissom J. R., Moore M. R. Progestin effects on growth in the human breast cancer cell line T-47D - possible therapeutic implications. Biochemical and Biophysical Research Communications. 145:1987;706-711.
33. Catherino W. H., Jeng M.-H., Jordan V. C. Norgestrel and gestodene stimulate breast cancer cell growth through an estrogen receptor mediated mechanism. British Journal of Cancer. 67:1993;945-952.
34. Schatz R. W., Soto A. M., Sonnenschein C. Effects of interaction between estradiol-17β and progesterone on the proliferation of cloned breast tumor cells (MCF-7 and T-47D). Journal of Cellular Physiology. 124:1985;386-390.
35. Markiewicz L., Hochberg R. B., Gurpide E. Intrinsic estrogenicity of some progestagenic drugs. Journal of Steroid Biochemistry and Molecular Biology. 41:1992;53-58.
36. Markiewicz L., Gurpide E. Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells. Journal of Steroid Biochemistry and Molecular Biology. 48:1994;89-94.
37. Botella J., Porthe-Nibelle J., Paris J., Lahlou B. Interaction of new 19-nor progesterone derivatives with progestagen, mineralocorticoid and glucocorticoid cytosolic receptors. Journal of Pharmacology. 17:1986;699-706.
38. Catherino W. H., Jordan V. C. Nomegestrol acetate a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. Journal of Steroid Biochemistry and Molecular Biology. 55:1995;239-246.
39. van der Berg B., Kalkhoven E., Isbrücker L., de Laat S. W. Effects of progestins on the proliferation of œstrogen-dependent human breast cancer cells under growth factor-defined conditions. Journal of Steroid Biochemistry and Molecular Biology. 42:1992;457-469.
40. Kloosterboer H. J., Schoonen W. G. E. J., Deckers G. H., Klijn J. G. M. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. Journal of Steroid Biochemistry and Molecular Biology. 49:1994;311-318.
41. Schoonen W. G. E. J., Joosten J. W. H., Kloosterboer H. J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. I. MCF-7 cell lines. Journal of Steroid Biochemistry and Molecular Biology. 55:1995;423-437.
42. Schoonen W. G. E. J., Joosten J. W. H., Kloosterboer H. J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. II. T-47D cell lines. Journal of Steroid Biochemistry and Molecular Biology. 55:1995;439-444.
43. Braunsberg H., Coldham N. G., Leake R. E., Cowan S. K., Wong W. Actions of the progestagen on human breast cancer cells: mechanisms of growth stimulation and inhibition. European Journal of Clinical Oncology. 23:1987;563-571.
44. Poulin R., Baker D., Poirier D., Labrie F. Multiple actions of synthetic "progestins" on the growth of ZR 75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Research and Treatment. 17:1990;197-210.
45. Hissom J. R., Bowden R. T., Moore M. R. Effects of progestins, estrogens and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T-47D. Endocrinology. 125:1989;418-423.
46. Nardulli A. M., Greene G. L., O'Malley B. W., Katzenellenbogen B. S. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology. 122:1988;935-944.
47. Alexander I. E., Shine J., Sutherland R. L. Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells. Molecular Endocrinology. 4:1990;821-828.
48. Saez S., Martin P. M., Chouvet C. D. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Research. 28:1978;3468-3473.
49. Classen S., Possinger K., Pelka-Fleischer R., Wilmanns W. Effects of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentrations of human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 45:1993;315-319.
50. Perez-Palacios G., Cerbon M. A., Pasapera A. M., Castro J. I., Enriquez J., Vilchis F., Garcia G. A., Morali G., Lemus A. E. Mechanisms of hormonal and antihormonal action of contraceptive progestins at the molecular level. Journal of Steroid Biochemistry and Molecular Biology. 41:1992;479-485.
51. Alexander I. E., Clarke C. L., Shine J., Sutherland R. L. Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. Molecular Endocrinology. 3:1989;1377-1386.
52. Nardulli A. M., Katzenellenbogen B. S. Progesterone receptor regulation in T-47D human breast cancer cells: analysis by density labelling of progesterone receptor synthesis and degradation and their modulation by progestins. Endocrinology. 122:1988;1532-1540.
53. Read L. D., Snider C. E., Miller J. S., Greene G. L., Katzenellenbogen B. S. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Molecular Endocrinology. 2:1988;263-271.
54. Colletta A. A., Howell F. V., Baum M. A novel binding site for a synthetic progestagen in breast cancer cells. Journal of Steroid Biochemistry. 33:1989;1055-1061.
55. Goldfine I. D., Papa V., Vignerie R., Siiteri P. K., Rosenthal S. Progestin regulation of insulin and insulin-like growth factor-I (IGF-I) receptors in cultured human breast cancer cells. Breast Cancer Research and Treatment. 22:1992;69-79.
56. Coutts A., Murphy L. J., Murphy L. C. Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens. Breast Cancer Research and Treatment. 32:1994;153-164.
57. Papa V., Hartmann K. K. P., Rosenthal S. M., Maddux B. A., Siiteri P. K., Goldfine I. D. Progestins induce down-regulation of insulin-like growth factor (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II. Molecular Endocrinology. 5:1991;709-717.
58. Yee D. The insulin-like growth factor system as target in breast cancer. Breast Cancer Research and Treatment. 32:1994;85-95.
59. Murphy L. C., Dotzlaw H. Endogenous growth factor expression in T-47D human breast cancer cells associated with reduced sensitivity to antiproliferative effects of progestins and antiestrogens. Cancer Research. 49:1989;599-604.
60. Murphy L. C., Dotzlaw H. Regulation of transforming growth factor-α and transforming growth factor-β messenger ribonucleic acid abundance in T-47D human breast cancer cells. Molecular Endocrinology. 3:1989;611-617.
61. Murphy L. C., Murphy L. J., Shiu R. P. C. Progestin regulation of EGF-receptor mRNA accumulation in T-47D human breast cancer cells. Biochemical and Biophysical Research Communications. 150:1988;192-196.
62. Murphy L. C., Murphy L. J., Dubik D., Bell G. I., Shiu R. P. C. Epidermal growth factor gene expression in human breast cancer cells: regulation of expression by progestins. Cancer Research. 48:1988;4555-4560.
63. Jeng M.-H., Jordan V. C. Growth stimulation and differential regulation of transforming growth factor-β1 (TGFβ1), TGFβ2, and TGFβ3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. Molecular Endocrinology. 5:1991;1120-1128.
64. Alkhalaf M., Murphy L. C. Regulation of c-jun and jun-B by progestins in T-47D human breast cancer cells. Molecular Endocrinology. 6:1992;1625-1633.
65. Wong M. M. S. J., Murphy L. C. Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 39:1991;39-44.
66. Moore M. R., Zhou J.-L., Blankenship K. A., Strobl J. S., Edwards D. P., Gentry R. N. A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene. Journal of Steroid Biochemistry and Molecular Biology. 62:1997;243-252.
67. Hurd C., Khattree N., Alban P., Nag K., Jhanwar S. C., Dinda S., Moudgil V. K. Hormonal regulation of the p53 tumor suppressor protein in T-47D human breast carcinoma cell line. Journal of Biological Chemistry. 270:1995;28507-28510.
68. Sutherland R. L., Hall R. E., Pang G. Y. N., Musgrove E. A., Clarke C. L. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Research. 48:1988;5084-5091.
69. Musgrove E. A., Hamilton J. A., Lee C. S., Sweeney K. J., Watts C. K., Sutherland R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology. 13:1993;3577-3587.
70. Kip1. Molecular Endocrinology. 11:1997;1593-1607.
71. Abul-Hajj Y. J., Iverson R., Kiang D. T. Aromatization of androgens by human breast cancer. Steroids. 33:1978;205-222.
72. Lipton A., Santner S. J., Santen R. J., Harvey H. A., Feil P. D., White-Hershey D., Bartholomew M. J., Antle C. E. Aromatase activity in primary and metastatic human breast cancer. Cancer. 59:1987;779-782.
73. Perel E., Daniilescu D., Kharlip L., Blankenstein M., Killenger D. W. Steroid modulation of aromatase activity in human cultured breast carcinoma cells. Journal of Steroid Biochemistry. 29:1988;393-399.
74. Dao T. L., Hayes C., Libby P. R. Steroid sulfatase activities in human breast tumors. Proceedings of the Society for Experimental Biology and Medicine. 146:1974;381-384.
75. Pasqualini J. R., Gelly C., Nguyen B.-L., Vella C. Importance of estrogen sulfates in breast cancer. Journal of Steroid Biochemistry. 34:1989;155-163.
76. Santner S. J., Feil P. D., Santen R. J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. Journal of Clinical Endocrinology and Metabolism. 59:1984;29-33.
77. Pasqualini J. R., Gelly C., Lecerf F. Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells. European Journal of Cancer and Clinical Oncology. 22:1986;1495-1501.
78. Prost O., Turrel M., Dahan N., Craveur C., Adessi G. L. Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma. Cancer Research. 44:1984;661-664.
79. Vignon F., Terqui M., Westley B., Derocq D., Rochefort H. Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology. 106:1980;1079-1086.
80. James V. H. T., McNeill J. M., Lai L. C., Newton C. J., Ghilchik M. W., Reed M. J. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids. 50:1987;269-279.
81. Pasqualini J. R., Chetrite G., Blacker C., Feinstein M.-C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. Journal of Clinical Endocrinology and Metabolism. 81:1996;1460-1464.
82. Chetrite, G. and Pasqualini, J. R., unpublished data.
83. Wilking N., Carlström K., Gustafsson S. A., Skoldefors H., Tollborn O. Oestrogen receptors and metabolism of œstrone sulfate in human mammary carcinoma. European Journal of Cancer. 16:1980;1339-1344.
84. Evans T. R. J., Rowlands M. G., Law M., Coombes R. C. Intratumoral œstrone sulphatase activity as a prognostic marker in human breast carcinoma. British Journal of Cancer. 69:1994;555-561.
85. Pasqualini, J. R., Chetrite, G., Nguyen, B.-L., Blacker, C., Feinstein, M.-C., Maloche, C., Talbi, M. and Delalonde, L., Control of estrone sulfatase activity and its expression in human breast cancer. In Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, ed. M. Motta and M. Serio. Excerpta Medica International Congress Series - ICS 1064. Elsevier Science B.V., Amsterdam, 1994, pp. 257-265.
86. Pasqualini J. R., Chetrite G., Le Nestour E. Control and expression of œstrone sulphatase activities in human breast cancer. Journal of Endocrinology. 150:1996;S99-S105.
87. Pasqualini J. R., Schatz B., Varin C., Nguyen B.-L. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 41:1992;323-329.
88. Pasqualini J. R., Nguyen B.-L. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs -independent human breast cancer cell lines. Breast Cancer Research and Treatment. 18:1991;93-98.
89. Prost-Avallet O., Oursin J., Adessi G. L. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology. 39:1991;967-973.
90. Santner S. J., Santen R. J. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by anti-estrogens. Journal of Steroid Biochemistry and Molecular Biology. 45:1993;383-390.
91. Pasqualini, J. R., Ebert, C. and Chetrite, G., Control of estradiol in human breast cancer. Effect of medrogestone on sulfatase, 17β-hydroxysteroid dehydrogenase and sulfotransferases activities in human breast cancer cells. In Proceedings of the IV European Congress on Menopause, Editions ESKA, Paris, 1998 (in press).
92. Pasqualini J. R., Varin C., Nguyen B.-L. Effect of the progestagen R-5020 (promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells: correlation with progesterone receptor levels. Cancer Letters. 66:1992;55-60.
93. Chetrite G., Paris J., Botella J., Pasqualini J. R. Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 58:1996;525-531.
94. Nguyen B.-L., Fermé I., Chetrite G., Pasqualini J. R. Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 46:1993;17-23.
95. Carlström K., Doberl A., Pousette A., Rannevik G., Wilking N. Inhibition of steroid sulfatase activity by danazol. Acta Obstetrica Gynecologica Scandinavica. 123:1984;107-111.
96. Evans T. R. J., Rowlands M. G., Jarman M., Coombes R. C. Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology. 39:1991;493-499.
97. Chetrite G., Kloosterboer H. J., Pasqualini J. R. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Research. 17:1997;135-140.
98. Chetrite G., Varin C., Delalonde L., Pasqualini J. R. Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the œstrone sulphatase activity of human breast cancer cells. Anticancer Research. 13:1993;931-934.
99. Pasqualini J. R., Maloche C., Maroni M., Chetrite G. Effect of the progestagen promegestone (R-5020) on mRNA of the œstrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Research. 14:1994;1589-1594.
100. Andersson S., Moghrabi N. Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenases. Steroids. 62:1997;143-147.
101. Isomaa V. V., Ghersevich S. A., Mäentausta O. K., Peltoketo E. H., Poutanen M. H., Vihko R. K. Steroid biosynthetic enzymes: 17β-hydroxysteroid dehydrogenase. Annals of Medicine. 25:1993;91-97.
102. Penning T. M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocrine Reviews. 18:1997;281-305.
103. Tait G. H., Newton C. J., Reed M. J., James V. H. T. Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. Journal of Molecular Endocrinology. 2:1989;71-80.
104. Pollow K., Boquoi E., Baumann J., Schmidt-Gollwitzer M., Pollow B. Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue. Molecular and Cellular Endocrinology. 6:1977;333-348.
105. Prudhomme J. F., Malet C., Gompel A., Lalardrie J. P., Ochoa C., Boue A., Mauvais-Jarvis P., Kuttenn F. 17β-Hydroxysteroid dehydrogenase activity in human breast epithelial cells and fibroblast cultures. Endocrinology. 114:1984;1483-1489.
106. Poutanen M., Moncharmont B., Vihko R. 17β-Hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Research. 52:1992;290-294.
107. Nguyen B.-L., Chetrite G., Pasqualini J. R. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol and promegestone (R-5020). Breast Cancer Research and Treatment. 34:1995;139-146.
108. Malet C., Vacca A., Kuttenn F., Mauvais-Jarvis P. 17β-Hydroxysteroid dehydrogenase (E2DH) activity in T47D cells. Journal of Steroid Biochemistry and Molecular Biology. 39:1991;769-775.
109. Pasqualini J. R., Chetrite G., Nguyen B.-L., Maloche C., Delalonde L., Talbi M., Feinstein M.-C., Blacker C., Botella J., Paris J. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. Journal of Steroid Biochemistry and Molecular Biology. 53:1995;407-412.
110. Fournier S., Brihmat F., Durand J. C., Sterkers N., Martin P. M., Kuttenn F., Mauvais-Jarvis P. Estradiol 17β-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency. Cancer Research. 45:1985;2895-2899.
111. Chetrite, G., Kloosterboer, H. J. and Pasqualini, J. R., Control by four organon compounds: tibolone and its metabolites (Org-4094, Org-30126, Org-OM38) on the formation of estradiol in human breast cancer cells. 79th Annual Meeting of the Endocrine Society, 1997, abstract.
112. Adams E. F., Coldham N. G., James V. H. T. Steroidal regulation of œstradiol-17β-dehydrogenase activity of the human breast cancer cell line MCF-7. Journal of Endocrinology. 118:1988;149-154.
113. Coldham N. G., James V. H. T. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity. International Journal of Cancer. 45:1990;174-178.
114. Couture P., Thériault C., Simard J., Labrie F. Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology. 132:1993;179-185.
115. Poutanen M., Isomaa V., Kainulainen K., Vihko R. Progestin induction of 17β-hydroxysteroid dehydrogenase enzyme protein in the T-47D human breast cancer cell line. International Journal of Cancer. 46:1990;897-901.
116. Anderson E., Howell A. Oestrogen sulphotransferases in malignant and normal human breast tissue. Endocrine-Related Cancer. 2:1995;227-233.
117. Falany J. L., Falany C. N. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Research. 56:1996;1551-1555.
118. Falany J. L., Lawing L., Falany C. N. Identification and characterization of cytosolic sulfotransferase activities in MCF-7 human breast carcinoma cells. Journal of Steroid Biochemistry and Molecular Biology. 46:1993;481-487.
119. Luu-The V., Bernier F., Dufort I. Steroid sulfotransferases. Journal of Endocrinology. 150:1996;587-597.
120. Pasqualini J. R. Steroid sulphotransferase activity in human hormone-independent MDA-MB-468 mammary cancer cells. European Journal of Cancer. 28A:1992;758-762.
121. Chetrite, G., Le Nestour, E. and Pasqualini, J. R., Estrogen sulfotransferase activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020). The Journal of Steroid Biochemistry & Molecular Biology 66 (1998) In press.
122. Pasqualini, J. R., Ebert, C. and Chetrite, G., Control of estradiol by medrogestone (prothil) in human breast cancer cells. 80th Annual Meeting of the Endocrine Society, 1998, abstract.
123. Harris A. L., Mitchell M. D., Smith I. E., Powles T. J. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Research. 42:1982;3405-3408.
124. Coombes R. C., Goss P. E., Dowsett M., Hutchinson G., Cunningham D., Jarman M., Brodie A. M. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids. 50:1987;245-252.
125. de Jong P. C., van de Ven J., Nortier H. W. R., Maitimu-Smeele I., Donker T. H., Thijssen J. H. H., Slee P. H. T. J., Blankenstein R. A. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor Vorozole. Cancer Research. 57:1997;2109-2111.
126. Miller W. R. Aromatase inhibitors. Endocrine-Related Cancer. 3:1996;65-79.
127. Lundgren S., Lonning P. E., Utaaker E., Aakvaag A., Kvinnsland S. Influence of progestins on serum hormone levels in post menopausal women with advanced breast cancer. I. General findings. Journal of Steroid Biochemistry. 36:1990;99-104.
128. Lundgren S., Lonning P. E. Influence of progestins on serum hormone levels in post menopausal women with advanced breast cancer. II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 36:1990;105-109.
129. Horwitz K. B., Wei L. L., Sedlacek S. M., D'Arville C. N. Progestin action and progesterone receptor structure in human breast cancer - a review. Recent Progress in Hormone Research. 41:1985;249-316.
130. Lundgren S. Progestins in breast cancer treatment - a review. Acta Oncologica. 31:1992;709-721.
131. Hellman I., Yoshida K., Zumoff B., Levin J., Kream J., Fukushima D. K. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. Journal of Clinical Endocrinology and Metabolism. 42:1976;912-917.